SEQUENTIAL CYCLES OF CISPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE & IFOSFAM

摘要：本研究的目的是评价两个周期的大剂量化疗方案(依托泊苷、顺铂和环磷酰胺)联合异环磷酰胺、卡铂和紫杉醇联合粒细胞集落刺激因子(G-CSF)和自体干细胞回输治疗晚期恶性肿瘤的可行性，评价这种方案的毒性，并确定在这种联合大剂量方案下紫杉醇的最大耐受量。医生资格摘要：经组织学证实的乳腺癌、卵巢癌、软组织肉瘤、恶性黑色素瘤、骨肉瘤、尤文氏肉瘤、肾母细胞瘤、胃肠道恶性肿瘤或小细胞癌；患者必须接受手术，且没有疾病证据，或必须对任何化疗、放射治疗或免疫治疗方案有完全缓解或部分缓解；生理年龄大于或等于18岁且小于或等于55岁；必须达到或超过80%的卡诺夫斯基表现状态(患者可以努力进行正常活动，一些疾病的迹象或症状)。

Physician Abstract: The objectives of this study are to evaluate the feasibility of administering two cycles of high dose chemotherapy (etoposide, cisplatin and cyclophosphamide) followed by (ifosfamide, carboplatin and taxol) each combined with G-CSF (Granulocyte Colony Stimulating Factor) and autologous stem cell reinfusion to patients with advanced malignancies, to evaluate the toxicities of such a regimen, and to define the maximum tolerated dose of taxol deliverable in this combined high dose regimen. Physician Eligibility Summary: Histologically proven diagnosis of Breast Cancer, ovarian Cancer, Soft Tissue Sarcoma, Malignant Melanoma, Osteosarcoma, Ewings's Sarcoma, Wilm's Tumor, Gastrointestinal Malignancies, or Small Cell Carcinoma; Patient must be surgically with No Evidence of Disease or must have had a Complete Response or Partial Response on any chemotherapeutic, radiotherapeutic, or immunotherapeutic regimen; Physiologic age greater than or equal to 18 and less than or equal to 55; Must meet or exceed a Karnofsky Performance Status of 80% (Patient can carry on normal activity with effort, some signs or symptoms of disease).